V
LightNews LightNews
banner
vtlvs.bsky.social
V
@vtlvs.bsky.social
100 followers 57 following 140 posts
23 ⛯ he/him 🏳️‍🌈 ⛯ mdnf
Posts Replies Media Videos
vtlvs.bsky.social
That makes sense, in that case you’re probably right when it comes to these platforms lol, I’ve been more on tt than here lately
September 9, 2025 at 1:12 AM
vtlvs.bsky.social
It’s not that it’s the same at all, tbh the problem comes in IMO when they start saying some shit like “clanker lover” and “clanka” and shit. It’s whatever by itself but people are making it way worse than it should be. And it’s only white ppl on tt I’ve seen doing shit like that
September 8, 2025 at 7:11 PM
Reposted by V
sailorrooscout.bsky.social
The research offers the first global estimate of both lives saved and life-years gained through COVID-19 vaccination between 2020 and 2024.

The study has been published in JAMA Health Forum. YES, it is PEER-REVIEWED
• jamanetwork.com/journals/jam...

🧪🧵⬇️
Key Points Question What was the global impact of COVID-19 vaccinations on deaths during the 2020-2024 period? Findings This comparative effectiveness study found that COVID-19 vaccinations averted 2.5 million deaths during 2020-2024 (sensitivity range estimates, 1.4-4.0 million) and saved 15 million life-years (sensitivity range estimates, 7-24 million life-years). The estimated benefits had a steep age gradient. Meaning COVID-19 vaccinations had a substantial benefit on global mortality during 2020-2024, but this benefit was mostly limited to a minority of the population of older individuals. Abstract Importance Estimating global lives and life-years saved is important to put into perspective the benefits of COVID-19 vaccination. Prior studies have focused mainly on the pre-Omicron period or only on specific regions, and lack crucial life-year calculations and often depend on strong modeling assumptions with unaccounted uncertainty. Objective To calculate the lives and life-years saved by COVID-19 vaccination worldwide from the onset of the vaccination campaigns and until October 1, 2024. Design, Setting, and Participants This comparative effectiveness study considered different strata of the worldwide population according to age, community-dwelling and long-term care residence status, pre-Omicron and Omicron periods, and vaccination before and after a SARS-CoV-2 infection. Exposures of doses. Any COVID-19 vaccination in any schedule and number Main Outcome Measure Death. Results In the main analysis, more than 2.5 million deaths were averted (1 death averted per 5400 vaccine doses administered). Eighty-two percent were among people vaccinated before any infection, 57% were during the Omicron period, and 90% pertained to people 60 years or older. Sensitivity analyses suggested 1.4 to 4.0 million lives were saved. Some sensitivity analyses showed a preponderance of the benefit during the pre-Omicron period. An estimated 14.8 million life-years were saved (1 life-year saved per 900 vaccine doses administered). The sensitivity range was 7.4 to 23.6 million life-years. Most life-years saved (76%) were among people 60 years or older, but long-term care residents contributed only 2% of the total. Children and adolescents (0.01% of lives saved and 0.1% of life-years saved) and young adults aged 20 through 29 years (0.07% of lives saved and 0.3% of life-years saved) had very small contributions to the total benefit. Conclusions and Relevance Estimates in this study are substantially more conservative than previous calculations focusing mostly on the first year of vaccination, but they still clearly demonstrate a major overall benefit from COVID-19 vaccination during the years 2020-2024. Most benefits in lives and life-years saved was secured for a portion of older persons, a minority of the global population.
September 2, 2025 at 4:03 PM
Reposted by V
sailorrooscout.bsky.social
What did the Lenacapavir studies show? Again, I previously wrote threads on these and you can find them here but I’ll give a quick summary as well.
• bsky.app/profile/sail...
• bsky.app/profile/sail...
sailorrooscout.bsky.social Chise @sailorrooscout.bsky.social · Mar 19
THIS IS HUGE! An HIV PrEP drug candidate in the form of a ONCE-yearly intramuscular injection has been shown to BLOCK HIV infections AND participants achieved AND maintained protection ABOVE the 95% efficacy threshold for UP TO 56 WEEKS. Phase III trials are scheduled for later this year! 🧪🧵⬇️
July 28, 2025 at 1:16 AM
Reposted by V
sailorrooscout.bsky.social
likely to stay on the medication if they only need to take the medication twice a year, rather than daily oral doses which is a substantial advantage of Lenacapavir.
July 28, 2025 at 1:15 AM
Reposted by V
sailorrooscout.bsky.social
one month a part. The overwhelming majority of PrEP users take daily versions, but it can be hard to take a pill every day when it's for prevention. So it is possible to see adherence levels as low as 50% to 55%, which does not provide adequate protection for at-risk populations. People are more
July 28, 2025 at 1:15 AM
Reposted by V
sailorrooscout.bsky.social
So, how does Lenacapavir compare to other HIV prevention drugs? Pre-exposure prophylaxis, or PrEP, medications are sold as a daily pill under brand names Truvada and Descovy, as well as generic versions. Another injectable medication, Apretude, is taken every two months after two initial shots taken
July 28, 2025 at 1:15 AM
Reposted by V
sailorrooscout.bsky.social
Lenacapavir has shown to be remarkably effective (I previously wrote in-depth threads on their clinical trials) and it only needs to be given twice a year, which represents a whole new way of preventing HIV. Keep in mind, Lenacapavir has been studied and developed over nearly TWO DECADES.
July 28, 2025 at 1:14 AM
Reposted by V
sailorrooscout.bsky.social
An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug that offers 100% protection with its twice-yearly injections. It's a landmark achievement that stands to save millions of lives across the globe.
July 28, 2025 at 1:10 AM